49P Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Glioblastoma (GBM) remains one of the most lethal brain cancers. CAR T cells targeting IL13Rα2 have shown tumour shrinkage and extended survival in some patients, but challenges remain, such as sustaining T-cell activity and overcoming the tumour microenvironment (TME). Here we show a new “armoured” CAR T (NS007) to better tackle the immunosuppressive TME and enhance persistence in solid tumours.
Authors
- Ying Yang (ORCID: https://orcid.org/0000-0001-7111-3641)
- Maurizio Mangolini (ORCID: https://orcid.org/0000-0002-0074-7935)
- Pietro Sormanni (ORCID: https://orcid.org/0000-0002-6228-2221)
- Matthew Greenig (ORCID: https://orcid.org/0000-0001-9366-9923)
- Biao Ma (ORCID: https://orcid.org/0000-0002-6387-0957)
- Liora M. Schultz (ORCID: https://orcid.org/0000-0001-9512-7597)
- Emily Souster
- Stanley Chukwudozie Onuoha (ORCID: https://orcid.org/0000-0002-6076-3910)
- Shaun Cordoba (ORCID: https://orcid.org/0009-0001-1519-3349)
- Saket Srivastava (ORCID: https://orcid.org/0000-0002-8072-7933)
- André Ramon (ORCID: https://orcid.org/0000-0002-7289-7916)
- R. Karatill
- D. Pombal
Institutions
- University of Cambridge (GB)
- Chimerix (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100860
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.28